C07K 2317/734
Complement-dependent cytotoxicity [cdc]
Official title: Complement-dependent cytotoxicity [CDC]
C07K2317/734 (Complement-dependent cytotoxicity [cdc]) appears on 1,204 US grants and 2,274 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,204
- Published applications
- 2,274
- Assignees
- 746
- Inventors
- 3,603
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 4 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 6 | 0 |
| 1997 | 12 | 0 |
| 1998 | 10 | 0 |
| 1999 | 7 | 0 |
| 2000 | 9 | 0 |
| 2001 | 8 | 3 |
| 2002 | 7 | 16 |
| 2003 | 9 | 24 |
| 2004 | 5 | 15 |
| 2005 | 6 | 40 |
| 2006 | 5 | 42 |
| 2007 | 11 | 50 |
| 2008 | 21 | 58 |
| 2009 | 18 | 85 |
| 2010 | 33 | 71 |
| 2011 | 38 | 87 |
| 2012 | 47 | 68 |
| 2013 | 53 | 104 |
| 2014 | 59 | 101 |
| 2015 | 70 | 108 |
| 2016 | 70 | 144 |
| 2017 | 71 | 77 |
| 2018 | 65 | 128 |
| 2019 | 64 | 126 |
| 2020 | 84 | 133 |
| 2021 | 64 | 133 |
| 2022 | 86 | 133 |
| 2023 | 70 | 130 |
| 2024 | 60 | 166 |
| 2025 | 74 | 130 |
| 2026 | 52 | 102 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- Means for specifically eliminating perilipin-1 fragment presenting adipocytes29 Sep 2026US 12,747,286 B2Alytas Therapeutics GmbH
- Anti-CD98hc antibody15 Sep 2026US 12,735,478 B2Osaka University
- Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof15 Sep 2026US 12,735,479 B2Shijiazhuang Yiling Pharmaceutical Co., Ltd.
- Il-5raxcd3e t cell engaging bispecific antibody and uses thereof8 Oct 2026US 2026/0308264 A1Ajou University Industry-Academic Cooperation Foundation
- Humanised antibodies and uses thereof24 Sep 2026US 2026/0284244 A1Telix Pharmaceuticals (Innovations) Pty Ltd.
- Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof24 Sep 2026US 2026/0285982 A1Regeneron Pharmaceuticals, Inc.
- Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer17 Sep 2026US 2026/0274947 A1Precision Biologics, Inc.
- Antibodies that bind to c-type lectin domain family 2 member d (clec2d)17 Sep 2026US 2026/0274965 A1Zumutor Biologics Inc.
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Polypeptide variants1,041US 6,194,551 B1Genentech, Inc. · 2001
- Chimeric antibody with specificity to human B cell surface antigen853US 5,500,362 AXoma Corporation · 1996
- Polypeptide variants521US 6,528,624 B1Genentech, Inc. · 2003
- Optimized Fc variants463US 7,317,091 B2Xencor, Inc. · 2008